Abbott Laboratories
DE ˙ XTRA ˙ US0028241000
75,22 € ↑1,20 (1,62%)
2026-06-03
AKTIENPREIS
SecurityDE:ABL / Abbott Laboratories
InstitutionGeneral Partner, Inc.
Latest Disclosed Ownership6,305 shares
Latest Disclosed Value $ 647,335
General Partner, Inc. reports 2.32% decrease in ownership of ABL / Abbott Laboratories

On April 8, 2026 - General Partner, Inc. filed a 13F-HR form disclosing ownership of 6,305 shares of Abbott Laboratories (DE:ABL) valued at $560,010 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 6, 2026 disclosing 6,455 shares of Abbott Laboratories. This represents a change in shares of -2.32% during the quarter. The current value of the position is $474,262 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-08 2026-03-31 13F Abbott Laboratories CL 002824100 6,305 -150 -2.32 647 -19.93 0.2510
2026-01-06 2025-12-31 13F Abbott Laboratories CL 002824100 6,455 0 0.00 809 -6.48 0.2875
2025-10-08 2025-09-30 13F Abbott Laboratories CL 002824100 6,455 0 0.00 865 -1.48 0.4760
2025-07-07 2025-06-30 13F Abbott Laboratories CL 002824100 6,455 0 0.00 878 2.45 0.5144
2025-04-04 2025-03-31 13F Abbott Laboratories CL 002824100 6,455 0 0.00 856 17.26 0.5577
2025-01-03 2024-12-31 13F Abbott Laboratories CL 002824100 6,455 0 0.00 730 -0.68 0.4398
2024-10-02 2024-09-30 13F Abbott Laboratories CL 002824100 6,455 0 0.00 736 9.70 0.4572
2024-07-05 2024-06-30 13F Abbott Laboratories CL 002824100 6,455 32 0.50 671 -8.22 0.4285
2024-04-01 2024-03-31 13F Abbott Laboratories CL 002824100 6,423 1,484 30.05 730 34.69 0.4586
2024-01-08 2023-12-31 13F Abbott Laboratories CL 002824100 4,939 0 0.00 543 13.87 0.4563
2023-10-10 2023-09-30 13F ABBOTT LABORATORIES CL 002824100 4,939 0 0.00 476 -11.52 0.4253
2023-07-03 2023-06-30 13F ABBOTT LABORATORIES CL 002824100 4,939 0 0.00 538 5.28 0.4488
2023-04-07 2023-03-31 13F ABBOTT LABORATORIES CL 002824100 4,939 0 0.00 511 -5.72 0.4493
2023-01-05 2022-12-31 13F ABBOTT LABORATORIES CL 002824100 4,939 4,939 542 0.4988
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.